UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 2, 2004
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
(609)-275-0500
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events.
On March 2, 2004, the Company's Board of Directors authorized the Company to
repurchase up to an additional 1.5 million shares of our common stock for an
aggregate purchase price not to exceed $40.0 million. We may repurchase shares
under this program through March 2005 either in the open market or in privately
negotiated transactions.
During 2003 and 2002, respectively, we repurchased approximately 1.5 million
and 100,000 shares of our common stock under previously authorized share
repurchase programs. The repurchase during 2003 occurred contemporaneously with
the issuance of $120 million aggregate principal amount of convertible
subordinated notes.
Item 7. Exhibits
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: March 8, 2004 By: /s/ Stuart M. Essig
-----------------------------
Stuart M. Essig
President and Chief Executive Officer